These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10375708)

  • 1. Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease.
    Yasojima K; McGeer EG; McGeer PL
    Brain Res; 1999 Jul; 833(2):297-301. PubMed ID: 10375708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early complement components in Alzheimer's disease brains.
    Veerhuis R; Janssen I; Hack CE; Eikelenboom P
    Acta Neuropathol; 1996; 91(1):53-60. PubMed ID: 8773146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques.
    Yasojima K; Schwab C; McGeer EG; McGeer PL
    Arterioscler Thromb Vasc Biol; 2001 Jul; 21(7):1214-9. PubMed ID: 11451754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement C1-inhibitor expression in Alzheimer's disease.
    Veerhuis R; Janssen I; Hoozemans JJ; De Groot CJ; Hack CE; Eikelenboom P
    Acta Neuropathol; 1998 Sep; 96(3):287-96. PubMed ID: 9754962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human heart generates complement proteins that are upregulated and activated after myocardial infarction.
    Yasojima K; Schwab C; McGeer EG; McGeer PL
    Circ Res; 1998 Oct; 83(8):860-9. PubMed ID: 9776733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease.
    Yang LB; Li R; Meri S; Rogers J; Shen Y
    J Neurosci; 2000 Oct; 20(20):7505-9. PubMed ID: 11027207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulated production and activation of the complement system in Alzheimer's disease brain.
    Yasojima K; Schwab C; McGeer EG; McGeer PL
    Am J Pathol; 1999 Mar; 154(3):927-36. PubMed ID: 10079271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and function of C1 inhibitor.
    Davis AE
    Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor.
    Veerhuis R; Janssen I; De Groot CJ; Van Muiswinkel FL; Hack CE; Eikelenboom P
    Exp Neurol; 1999 Nov; 160(1):289-99. PubMed ID: 10630213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
    Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
    J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease.
    Walker DG; Yasuhara O; Patston PA; McGeer EG; McGeer PL
    Brain Res; 1995 Mar; 675(1-2):75-82. PubMed ID: 7796155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium.
    Väkevä A; Morgan BP; Tikkanen I; Helin K; Laurila P; Meri S
    Am J Pathol; 1994 Jun; 144(6):1357-68. PubMed ID: 7515561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood.
    Landsem A; Nielsen EW; Fure H; Christiansen D; Ludviksen JK; Lambris JD; Østerud B; Mollnes TE; Brekke OL
    Clin Exp Immunol; 2013 Aug; 173(2):217-29. PubMed ID: 23607270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurons express proteins of the classical complement pathway in Alzheimer disease.
    Terai K; Walker DG; McGeer EG; McGeer PL
    Brain Res; 1997 Sep; 769(2):385-90. PubMed ID: 9374211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A secondary C1s interaction site on C1-inhibitor is essential for formation of a stable enzyme-inhibitor complex.
    He S; Sim RB; Whaley K
    FEBS Lett; 1997 Mar; 405(1):42-6. PubMed ID: 9094421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema.
    Jackson J; Sim RB; Whaley K; Feighery C
    J Clin Invest; 1989 Feb; 83(2):698-707. PubMed ID: 2536404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous C1-inhibitor production and expression in the heart after acute myocardial infarction.
    Emmens RW; Baylan U; Juffermans LJ; Karia RV; Ylstra B; Wouters D; Zeerleder S; Simsek S; van Ham M; Niessen HW; Krijnen PA
    Cardiovasc Pathol; 2016; 25(1):33-9. PubMed ID: 26476955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The critical concentration of C1-esterase inhibitor (C1-INH) in human serum preventing auto-activation of the first component of complement (C1).
    Windfuhr JP; Alsenz J; Loos M
    Mol Immunol; 2005 Apr; 42(6):657-63. PubMed ID: 15781109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions.
    Oleesky DA; Daniels RH; Williams BD; Amos N; Morgan BP
    Clin Exp Immunol; 1991 May; 84(2):250-5. PubMed ID: 2025952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes.
    Gasque P; Morgan BP
    Immunology; 1996 Nov; 89(3):338-47. PubMed ID: 8958045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.